
Shares of Teladoc Health Inc (NYSE:TDOC) are surging Friday morning after Citron Research posted bullish comments on the telehealth provider, asserting they were “not wrong, just early” on the stock’s potential. The commentary sparked renewed investor interest, pushing the stock higher in early trading.
What To Know: Citron’s renewed confidence stems from the performance of Teladoc’s chronic care division, Livongo. The firm highlighted a recent Bank of America report indicating that Livongo’s usage had jumped 55% year-over-year, marking the most significant increase since January 2025.